The post Solana Pushes Urgent Validator Update as Network Stability Tightens appeared on BitcoinEthereumNews.com. Solana has rolled out an urgent validator updateThe post Solana Pushes Urgent Validator Update as Network Stability Tightens appeared on BitcoinEthereumNews.com. Solana has rolled out an urgent validator update

Solana Pushes Urgent Validator Update as Network Stability Tightens

Solana has rolled out an urgent validator update, v3.0.14, now recommended for general use across Mainnet-Beta. The release targets both staked and unstaked validators, including test nodes, and signals the network’s continued focus on operational resilience. 

According to Solana Status, validators should apply the patch immediately to reduce exposure to potential disruptions. Consequently, the update reinforces Solana’s approach of deploying preventative fixes before issues affect users or applications.

Validator Update Reinforces Network Reliability

The v3.0.14 release continues a pattern of rapid maintenance updates across Solana’s v3 validator client series. Besides addressing potential vulnerabilities, these patches aim to strengthen long-term performance and stability. 

Developers often push such updates quietly, ensuring validators install them before any network impact becomes visible. Hence, the absence of a detailed changelog aligns with Solana’s emphasis on proactive defense.

Additionally, rising on-chain activity has increased the importance of validator reliability. The recent launch of the SKR token highlights growing demand across DeFi, NFTs, and tokenized real-world assets.

Stable validator layer supports higher throughput and smoother user experiences. Consequently, the network continues prioritizing infrastructure hardening alongside ecosystem growth.

Major Upgrades Shape Solana’s Roadmap

Moreover, Solana’s broader roadmap includes structural upgrades designed to address congestion and decentralization concerns. The Alpenglow upgrade, introduced in September 2025, replaced legacy consensus components with Votor and Rotor. 

These changes target faster finality and parallel execution, improving scalability. The network plans mainnet deployment this year, expanding capacity for complex applications.

Significantly, the Firedancer validator client also plays a central role. Released in Q1 2025 by Jump Crypto, Firedancer runs alongside the Agave client. Its modular design enables parallel processing and targets extremely high throughput. 

The Agave 3.0.6 release, recommended in October, further supported validator efficiency. Together, these upgrades aim to future-proof Solana’s infrastructure.

SOL Price Structure Reflects Compression and Accumulation

Source: CoinCodex

However, SOL price action shows near-term caution despite structural optimism. Solana traded near $135.31, posting a mild daily decline while maintaining a weekly gain above 2%. Market capitalization hovered near $76.3 billion, supported by steady circulation levels. 

According to moonbag, SOL’s long-term chart structure supports a breakout toward higher psychological levels, with $400 emerging as a potential upside target. Weekly price compression within a symmetrical triangle suggests prolonged accumulation. Resistance near $260 remains critical, while sustained strength above $180 could unlock higher targets.

Source: X

Eljaboom highlighted improving short-term structure after SOL reclaimed the $135–$138 demand zone. Additionally, higher lows continue forming, which limits downside risk. Analysts see $145 as a near-term pivot, with $187 emerging as a key resistance level ahead of February.

Source: https://coinpaper.com/13667/solana-urges-validators-to-install-v3-0-14-update-as-analysts-eye-187-before-february

Market Opportunity
Nowchain Logo
Nowchain Price(NOW)
$0.0012761
$0.0012761$0.0012761
+24.72%
USD
Nowchain (NOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26